Company Overview
BioCryst Pharmaceuticals, Inc. operates as a biotechnology company focused on the development and commercialization of medicines designed to treat hereditary angioedema (HAE) and other rare diseases, while also marketing peramivir injection as an intravenous neuraminidase inhibitor for acute uncomplicated and seasonal influenza. The firm functions within the healthcare sector, specifically under the industry classification of drug manufacturers specializing in specialty and generic pharmaceuticals, a segment characterized by high R&D requirements and often limited competition for specific therapeutic areas. As of the latest data, the company holds a market capitalization of $2.43B and generated annual revenue of $874.84M, employing a workforce of 435 individuals to execute its operational strategy. These financial dimensions indicate that BioCryst has established a significant position within the specialty drug market, generating revenue levels that support a substantial enterprise value despite the niche nature of its primary therapeutic indications.
Financial Health
The company reported a trailing twelve-month revenue of $874.84M, accompanied by a net income of $263.86M and an EBITDA of $350.79M. The substantial gap between revenue and net income reveals an efficient cost structure, evidenced by a gross margin of 79.3%, which suggests high pricing power or low cost of goods sold typical of specialized pharmaceutical products. Furthermore, the operating margin stands at 65.6%, while the profit margin reaches 30.2%, indicating that the company retains a significant portion of each sales dollar after covering both operating expenses and taxes. The firm generated free cash flow of $256.42M, a metric that provides critical insight into its financial flexibility to fund ongoing research, development, and potential strategic acquisitions without relying solely on external capital markets. Regarding liquidity and leverage, BioCryst maintains cash reserves of $274.75M against total debt of $477.33M, resulting in a debt-to-equity ratio that is not explicitly calculated in the provided metrics but is contextualized by a current ratio of 2.06. This current ratio indicates a robust short-term liquidity position, as the company holds more than twice the current assets necessary to cover its current liabilities. Additionally, the return on assets is reported at 43.2%, demonstrating highly effective utilization of its asset base, whereas return on equity is listed as N/A, suggesting that the equity base calculation may involve adjustments common in biotechnology firms with significant intangible assets or specific accounting treatments.
Valuation Assessment
BioCryst Pharmaceuticals trades with a trailing P/E ratio of 8.02 and a forward P/E ratio of 12.09. The difference between these two metrics implies that the market anticipates a growth trajectory in earnings, as the forward multiple is higher than the trailing multiple, reflecting expectations of future profitability expansion. The price-to-book ratio is listed at -17.35, a negative figure that indicates the market capitalization is significantly below the company's book value, a scenario often seen in biotech firms where intangible assets are valued differently on the balance sheet than in the market. Alternative valuation metrics such as the price-to-sales ratio of 2.78 and an EV/EBITDA of 7.51 provide additional context, suggesting that the stock is valued at a reasonable multiple of its sales and earnings before interest, taxes, depreciation, and amortization relative to peers. In terms of trading range, the 52-week high is $11.31 and the 52-week low is $6.00, meaning the current price sits somewhere within this band, reflecting recent market volatility. The stock exhibits a beta of 0.76, which indicates that its price volatility is lower than the broader market, suggesting it may act as a defensive position within a healthcare portfolio during periods of market turbulence.
Growth & Income
The company demonstrated a revenue growth rate of 209.1% year-over-year, while earnings growth is listed as N/A. The absence of reported earnings growth data precludes a direct comparison of earnings expansion against revenue expansion in this specific reporting period, though the massive revenue increase suggests a rapid scaling of commercial operations or successful product launches. As a non-dividend payer, BioCryst maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company currently reinvests all available earnings into research, development, and commercial growth rather than distributing cash to shareholders. This strategy is common in the specialty pharmaceutical sector where capital is prioritized for pipeline advancement to sustain long-term market presence. The overall growth and income profile is defined by exceptional revenue expansion coupled with a complete retention of earnings, positioning the firm for potential future capital appreciation rather than current income generation.